Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications
about
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line ModelTrastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.
P2860
Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Neoadjuvant therapy of early s ...... ence and clinical implications
@ast
Neoadjuvant therapy of early s ...... ence and clinical implications
@en
Neoadjuvant therapy of early s ...... ence and clinical implications
@nl
type
label
Neoadjuvant therapy of early s ...... ence and clinical implications
@ast
Neoadjuvant therapy of early s ...... ence and clinical implications
@en
Neoadjuvant therapy of early s ...... ence and clinical implications
@nl
prefLabel
Neoadjuvant therapy of early s ...... ence and clinical implications
@ast
Neoadjuvant therapy of early s ...... ence and clinical implications
@en
Neoadjuvant therapy of early s ...... ence and clinical implications
@nl
P2860
P356
P1476
Neoadjuvant therapy of early s ...... ence and clinical implications
@en
P2093
S. Pernas Simon
P2860
P304
P356
10.1177/1758834014535650
P407
P577
2014-09-01T00:00:00Z